Skip to content
MenuOpen navigation menu

Real moms, real GLP-1 talk

There Is a Dose Above Mine Now. I Went and Read What It Buys.

Tripling the dose adds 3.3 percentage points of weight loss. It also takes altered skin sensation from 6% to 22%. The trade, read off the label.

Walked and written by Jenna Marsh — a mom doing this herself, not a treating clinician
On this page

The thing I did not know existed

I have been sitting at 2.4 mg for a while, which for a long time was the top of the ladder. It is not any more. There is an approved 7.2 mg version of the same injection now2, and the label says that after at least four weeks at 2.4 mg, if more weight reduction is clinically indicated, the dose can go up to a maximum of 7.2 mg once weekly1.

I have not taken it and I am not asking for it this week. But I did what I always do, which is go and read the actual prescribing information instead of the forum thread. Here is what three times the dose actually buys, and what it charges you for it.

What it buys

In a 72-week trial of adults with obesity, mean weight change was −3.9% on placebo, −15.5% on 2.4 mg, and −18.8% on 7.2 mg1.

At 72 weeksPlacebo2.4 mg7.2 mg
Weight change−3.9%−15.5%−18.8%
Lost ≥10%20.3%72%79.8%
Lost ≥15%7.5%52.3%63.8%
Lost ≥20%2.8%32.3%45.5%
Nausea13%35%39%
Vomiting6%16%22%
Hair loss1%3%6%
Altered skin sensation0.3%6%22%

Tripling the dose moved the average by 3.3 percentage points — the label puts the difference from 2.4 mg at −3.3, with a confidence interval of −4.9 to −1.61. Three points. That is what triple buys on average.

The bottom row of that top section is the better argument for it. The share of people losing at least a fifth of their body weight went from about a third to nearly half. If you are someone for whom 2.4 mg produced a real but not-enough result, that is not nothing, and it is the honest case for asking.

What it charges you

I expected the cost to be nausea. Nausea barely moved — 35% to 39%.

The one that moved is a side effect I had never heard of. Dysesthesia: 6% at my dose, 22% at 7.2 mg, 0.3% on placebo1.

The label groups it with related events of altered skin sensation — pins and needles, skin that hurts, skin that feels oversensitive, a burning feeling on the skin — and states plainly that the incidence increased with increasing dose and with drug levels in the blood1. More than one in five. That is not a footnote-level side effect.

Then the part that decided it for me, at least for now. Of 288 people who got it on the higher dose: 2% stopped the drug permanently, 8% paused, and 23% cut their dose. Most of the people who did something about it recovered, and the events resolved faster when something was done. But 18% had not reported recovering by the end of the trial — and the label notes that in most of those, the dose had been left unchanged1.

And of the people who recovered and then went back up to 7.2 mg — 38 of them — 17, or 45%, had it come back1.

The one I am still thinking about

There is a paragraph in the immunogenicity section that I have not seen anyone mention.

Over the 72 weeks, 15.4% of people on 7.2 mg developed antibodies to semaglutide, against 11.2% on 2.4 mg. Some of those antibodies cross-reacted with native GLP-1 — the hormone your own body makes. That was 36 of the 1,311 people on the higher dose, about 2.7%, against 3 of 304 on 2.4 mg, about 1.0%1.

The label's own next sentence is the honest one: the clinical consequences of antibodies that cross-react with native GLP-1 are unknown1. It also says no clinically significant effect on how the drug behaves in the body was seen, and that there is not enough evidence to characterize the effects on safety or effectiveness.

So it is not a warning. It is a blank space, and it is a slightly bigger blank space at the higher dose. I would want to know that before I tripled anything.

What I would ask, if I ask

  • "Am I actually stalled, or am I impatient?" Hitting a plateau is a different problem from a dose that never worked, and only one of them is a dosing question.
  • "What do we do if my skin starts feeling strange?" Given that most people who acted on it recovered and 18% of those who did not act had not recovered, I would want that plan agreed in advance rather than improvised.
  • "Is three points worth it for me?" For some people it plainly is. I would rather answer that on purpose than drift upward by default.

My hair is already thinner than it was — what actually helped — and that row doubles at the higher dose too. For now I am staying where I am. But I would rather know the dose above me exists, and what it costs, than find out from someone else's before-and-after.

I am a mother who reads labels, not a clinician, and none of this is medical advice.

Frequently asked questions

How much more weight do you lose on Wegovy 7.2 mg?

About three percentage points more on average. In a 72-week trial, mean weight change was 15.5% on 2.4 mg and 18.8% on 7.2 mg, and the label gives the difference from 2.4 mg as 3.3 percentage points with a confidence interval of 1.6 to 4.9. The bigger difference is in the tail: 45.5% of people on the higher dose lost at least 20% of their body weight, against 32.3% on 2.4 mg.

What are the side effects of the 7.2 mg dose?

Nausea barely changes, going from 35% to 39%. The reaction that changes most is dysesthesia — altered skin sensation such as tingling, skin pain, oversensitive skin or a burning feeling — reported by 22% on 7.2 mg against 6% on 2.4 mg and 0.3% on placebo. Vomiting rises from 16% to 22% and hair loss from 3% to 6%.

Does the skin sensation from Wegovy go away?

Often, but not always. Among 288 people who experienced it on 7.2 mg, 2% stopped permanently, 8% paused and 23% reduced their dose, and most who took one of those actions recovered — faster than those who did nothing. But 18% had not reported recovering by the end of the trial, mostly people whose dose was left unchanged. Of 38 who recovered and went back up to 7.2 mg, 17 had it return.

How do you get to the 7.2 mg dose?

The label says that after at least four weeks on the 2.4 mg dose, if additional weight reduction is clinically indicated, the dosage may be increased to a maximum of 7.2 mg once weekly. It is a decision for your prescriber, not an automatic next step.

What are the antibodies mentioned in the Wegovy label?

Over 72 weeks, 15.4% of people on 7.2 mg developed anti-semaglutide antibodies against 11.2% on 2.4 mg. A subset had antibodies that cross-reacted with native GLP-1, the hormone the body makes itself — 36 of 1,311 people on the higher dose, about 2.7%, against about 1.0% on 2.4 mg. The label states the clinical consequences of these are unknown.

References

  1. Novo Nordisk Inc. (2026). WEGOVY (semaglutide) injection and tablets — Prescribing Information: section 2 Dosage and Administration (maximum 7.2 mg once weekly after at least 4 weeks at 2.4 mg), section 6.1 adverse reactions in Studies 8 and 9 (placebo N=303, 2.4 mg N=304, 7.2 mg N=1,311) including the dysesthesia narrative, section 6.2 Immunogenicity, and section 14 Table 12 results. DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. U.S. Food and Drug Administration (2026). Drugs@FDA: FDA-Approved Drugs — WEGOVY, NDA 215256, Novo Nordisk (approval record for the semaglutide injection product family). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

One mom to another, not a doctor: everything here is for learning and figuring out your options, not medical advice, a diagnosis, or a plan for your body. GLP-1 medicines aren't for use in pregnancy or while you're trying to conceive. Before you start, stop, or change anything, talk it through with a clinician who actually knows your history.

Continue reading